Overview

LIBERATE Trial in COVID-19

Status:
Recruiting

Trial end date:
2021-09-25

Target enrollment:

Participant gender:

Summary

The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.

Phase:

Phase 4

Details

Lead Sponsor:

King's College London

Collaborator:

Guy's & St Thomas NHS Foundation Trust

Treatments:

Ibuprofen